top of page

Our Team

DSC07489.jpg

Ian Welsford

CEO, Founder WCLLC

PhD

Dr. Welsford is the managing consultant for WCLLC and has 39 years of experience in device, biologics, small and large molecule drug discovery, SaMD, AI/ML, health tech and combination product compliance and commercialization.  With over 30 QMS implementations across these domains, Dr. Welsford has also supported varying regulatory clearances, licensure and approvals in the US, Canada, Mexico, LATAM, EU, ASEAN, China and EMEA as well as designed and managed clinical trials in the US and OUS.  An experienced auditor, Dr. Welsford has supported a variety of audits at varying stages of commercial launch. 

DSC07490.jpg

Wesley Welsford

Executive Consultant

MBA, M.S., PMP

Wes is a Regulatory, Quality, and Clinical Consultant for Medical Device and Biotech firms with an MBA in Healthcare Systems and an MS in Homeland Security and Emergency Management. His expertise is in high-stakes operational oversight, clinical quality systems, and regulatory compliance. He is a Certified Project Management Professional (PMP) with a specialized Graduate Certificate in Healthcare Quality and Patient Safety. Wes has a proven track record in navigating complex regulatory landscapes, managing institutional risk, and optimizing healthcare delivery systems. 

Our Values

We deliver fairly priced, efficient, and highly effective RA/QA/CA strategies tailored specifically to the unique needs of Med Tech and Bio Tech startups. Unlike larger firms that offer only high-level oversight, we pride ourselves on getting "in the weeds" with our clients to truly understand their business, product, and organizational culture. This agility allows us to plug seamlessly into your team at any stage of development, building customized compliance solutions while uniquely integrating the entire journey, from early-stage technology development all the way through to reimbursement.

Our Success Metrics

Helped 1 IVD  get acquired by top 10 med tech company
Oversaw 3 acquisitions of med tech companies by NASDAQ 100 strategic partners
Supported  2 companies ($400M & $250M valuation) in the drug delivery space through IPO
Set up 37 quality systems in biotechs, theranostics, combination products, SaMDs, AI companies, IVDs across  areas of healthtech, neuromodulation, cardiovascular, diabetes, cancer and nephrology
bottom of page